Phase I study of GC1008 (fresolimumab): a human anti‐transforming growth factor‐beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma
Open accessThe DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
BACKGROUND: In advanced cancers, transforming growth factor-beta (TGFβ) promotes tumor growth and metastases and suppresses host antitumor immunity. GC1008 is a human anti-TGFβ monoclonal antibody that neutralizes all isoforms of TGFβ. Here, the safety and activity of GC1008 was evaluated in patients with advanced malignant melanoma and renal cell carcinoma. METHODS: In this multi-center phase I trial, cohorts of patients with previously treated malignant melanoma or renal cell carcinoma received intravenous GC1008 at 0.1, 0.3, 1, 3, 10, or 15 mg/kg on days 0, 28, 42, and 56. Patients achieving at least stable disease were eligible to receive Extended Treatment consisting of 4 doses of GC1008 every 2 weeks for up to 2 additional courses. Pharmacokinetic and exploratory biomarker assessments were performed. RESULTS: Twenty-nine patients, 28 with malignant melanoma and 1 with renal cell carcinoma, were enrolled and treated, 22 in the dose-escalation part and 7 in a safety cohort expansion. No dose-limiting toxicity was observed, and the maximum dose, 15 mg/kg, was determined to be safe. The development of reversible cutaneous keratoacanthomas/squamous-cell carcinomas (4 patients) and hyperkeratosis was the major adverse event observed. One malignant melanoma patient achieved a partial response, and six had stable disease with a median progression-free survival of 24 weeks for these 7 patients (range, 16.4-44.4 weeks). CONCLUSIONS: GC1008 had no dose-limiting toxicity up to 15 mg/kg. In patients with advanced malignant melanoma and renal cell carcinoma, multiple doses of GC1008 demonstrated acceptable safety and preliminary evidence of antitumor activity, warranting further studies of single agent and combination treatments. TRIAL REGISTRATION: Clinicaltrials.gov NCT00356460.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures






Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“Fresolimumab, a human monoclonal antibody against TGF‐β in a phase 1 clinical trial (NCT00356460), demonstrated preliminary evidence of anti‐tumor activity in malignant melanoma and renal cell carcinoma [42].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [42]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Improved survival with vemurafenib in melanoma with BRAF V600E mutation
Chapman, P. B., Hauschild, A., Robert, C., Haanen, J. B., Ascierto, P., Larkin, J., Dummer, R., Garbe, C., Testori, A., Maio, M., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1103782 · Cited by 7,720 · cited 4×
“Recently, targeted therapies directed against B-RAF and other genes have been used successfully to treat patients with MM [33].”
BackgroundInfluentialMassagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.07.001 · Cited by 3,907
Tumor Self-Seeding by Circulating Cancer Cells
Kim, M.-Y., Oskarsson, T., Acharyya, S., Nguyen, D. X., Zhang, X. H.-F., Norton, L., & Massagué, J. (2009) · Cell · doi:10.1016/j.cell.2009.11.025 · Cited by 1,335 · cited 1×
“Norton and Massague [48,49] have proposed that cancer cell migration and ‘‘re-seeding’’ of the primary tumor with cells primed for metastatic growth leads to a tumor with heterogenous subpopulations of aggressive, rapidly growing cancer cells that may become resistant to treatment.”
BackgroundRAS Mutations in Cutaneous Squamous-Cell Carcinomas in Patients Treated with BRAF Inhibitors
Su, F., Viros, A., Milagre, C., Trunzer, K., Bollag, G., Spleiss, O., Reis-Filho, J. S., Kong, X., Koya, R. C., Flaherty, K. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1105358 · Cited by 1,038
TGFβ Primes Breast Tumors for Lung Metastasis Seeding through Angiopoietin-like 4
Padua, D., Zhang, X. H.-F., Wang, Q., Nadal, C., Gerald, W. L., Gomis, R. R., & Massagué, J. (2008) · Cell · doi:10.1016/j.cell.2008.01.046 · Cited by 952
Roberts, A. B., Anzano, M. A., Lamb, L. C., Smith, J. M., & Sporn, M. B. (1981) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.78.9.5339 · Cited by 919 · cited 1×
“Transforming growth factor-beta (TGFb) is a pleiotropic cytokine that is a member of a superfamily of ligands that includes bone morphogenetic proteins and activins [1,2].”
BackgroundKorn, E. L., Liu, P.-Y., Lee, S. J., Chapman, J.-A. W., Niedzwiecki, D., Suman, V. J., Moon, J., Sondak, V. K., Atkins, M. B., Eisenhauer, E. A., et al. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.12.7837 · Cited by 705
Terabe, M., Matsui, S., Park, J.-M., Mamura, M., Noben-Trauth, N., Donaldson, D. D., Chen, W., Wahl, S. M., Ledbetter, S., Pratt, B., et al. (2003) · The Journal of Experimental Medicine · doi:10.1084/jem.20022227 · Cited by 539
Self-citationTransforming Growth Factor-β and the Immune Response: Implications for Anticancer Therapy
Wrzesinski, S. H., Wan, Y. Y., & Flavell, R. A. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1157 · Cited by 452 · cited 2×
“With broad activity in natural killer (NK) cells, T cells including T regulatory cells, NKT cells, monocytes/ macrophages, and dendritic cells, TGFb can down-regulate both primary and secondary immune responses and suppress antitumor effector cells [3,11,12].”
Background
Cited by
Items 401–500 of 508
CAR-NK cell immunotherapy: Development and challenges toward an off-the-shelf product
Mansour, A. G., Teng, K., Lu, T., Barr, T., & Yu, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-824375-6.00011-4 · Cited by 4
Identification of Immune Function-Related Subtypes in Cutaneous Melanoma
Liu, L., Zhu, J., Jin, T., Huang, M., Chen, Y., Xu, L., Chen, W., Jiang, B., & Yan, F. (2021) · Life · doi:10.3390/life11090925 · Cited by 3
“In recent years, inhibitors targeting TGF-β pathway have been discovered and investigated by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now, such as Phase I study of GC1008 (fresolimumab), Ph II study of NCT01453361 (Gemogenovatucel-T) and so on [58,59].”
BackgroundChen, J., Shi, X., Xiao, L., Li, Z., Li, Z., & Sun, L. (2022) · Cancer Medicine · doi:10.1002/cam4.4752 · Cited by 5
Mavroudis, P. D., Pillai, N., Wang, Q., Pouzin, C., Greene, B., & Fretland, J. (2022) · CPT Pharmacometrics & Systems Pharmacology · doi:10.1002/psp4.12857 · Cited by 3
de Souza, J. C., Junior, R. S. R., Pimenta, T. M., Martins, B. D. S., & Rangel, L. B. A. (2023) · Journal of Cancer Metastasis and Treatment · doi:10.20517/2394-4722.2022.91 · Cited by 6
Ramzan, A., Yousaf, M. A., Rashid, M. U., Basheera, S., & Malkani, N. (2023) · Journal of Biomolecular Structure and Dynamics · doi:10.1080/07391102.2023.2268198 · Cited by 3
“Phase I studies indicate that Fresolimumab exhibits antitumor activity in individuals diagnosed with advanced renal cell carcinoma and malignant melanoma (Morris et al., 2014).”
Cytokine Networks and Cancer Stem Cells
Liongue, C., Ward, A. C., Duan, W., & Shigdar, S. L. (2015) · Springer eBooks · doi:10.1007/978-3-319-21030-8_3 · Cited by 3
Recent Progress in Stem Cell Research of the Pituitary Gland and Pituitary Adenoma
Toda, M., Tamura, R., & Toda, M. (2020) · Endocrines · doi:10.3390/endocrines1010006 · Cited by 3
“Inhibitors that target TGF-β receptor I kinase [52] and Wnt/β-catenin [53] might be useful to treat progressive PAs.”
BackgroundTargeting TGF-β: Triumphs and Challenges
Acharya, B., Miah, S., & Frett, B. (2022) · Future Medicinal Chemistry · doi:10.4155/fmc-2021-0344 · Cited by 4
Squamous Cell Carcinoma and its Precursors
Gupta, G., & Dirschka, T. (2024) · Wiley eBooks · doi:10.1002/9781119709268.rook140 · Cited by 4
Fifty Shades of PSMA-Avid Rib Lesions: A Comprehensive Review
Shamshirgaran, A., Samadi, M. H., Saeed, M., Harsini, S., Sahafi, P., Divband, G., Mohammadi, G., Ayati, N., Sadeghi, R., Rizzo, A., et al. (2025) · Cancers · doi:10.3390/cancers17213404 · Cited by 3
Tawfeek, H. A. W. (2025) · Journal of the Endocrine Society · doi:10.1210/jendso/bvaf221 · Cited by 2
“Importantly, an antihuman TGF-β neutralizing antibody, fresolimumab, has been extensively evaluated in humans for treatment of cancer and was well-tolerated up to 15 mg/kg [262].”
Sahoo, S., Kashyap, A., Muduly, D. K., & Sahoo, S. K. (2026) · Phytotherapy Research · doi:10.1002/ptr.70194 · Cited by 2
“Another anti- TGF-β monoclonal antibody, SAR439459, exhibits a synergistic anti-cancer effect combined with PD-1 blockade, thus enhancing anti-tumor immunity in a preclinical study (Morris et al. 2014).”
Parsa, S., Sarkani, E. O., Chaleshtori, Z. M., Darash, S., Fotros, N., Iraj, K. M., Ehsani, F. Z., Naeini, Y. M., Yahyazadeh, S., Fatehpour, M., et al. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116454 · Cited by 3
Advancing precision medicine in pancreatic cancer using novel biomarkers and clinical targets
Murthy, D., Seyhan, A. A., den Hollander, P., Lu, S., Kuburich, N. A., Gould, C., Karam, A., Sun, K., Schupp, P. G., Safran, H., et al. (2026) · Molecular Aspects of Medicine · doi:10.1016/j.mam.2026.101476 · Cited by 3
Pelletier, M. R., Yang, J., Joshi, M., Grauel, A. L., Abecunas, C., Altzerinakou, M., Zhou, Z., Zhu, X., Clark, K., Li, L., et al. (2026) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-26-0805 · Cited by 3
“Fresolimumab, a mAb targeting all isoforms of TGF β , showed promise in early-phase clinical trials for melanoma, renal cell carcinoma, and non–small cell lung cancer, but it encountered significant hurdles in later-stage trials, leading to its discontinuation in oncology (43).”
Transforming Growth Factor Beta (TGF-β) Signaling in Head and Neck Squamous Cell Carcinoma (HNSCC)
Kudinov, A. E., & Beck, T. N. (2018) · Current cancer research · doi:10.1007/978-3-319-78762-6_4 · Cited by 3
Hall, P., Cauvin, A. J., Dudal, S., Raymond, J., Rogerson, P., & Jolette, J. (2020) · Toxicologic Pathology · doi:10.1177/0192623320960023 · Cited by 2
“G4 (IgG4) monoclonal antibody inhibitor, resulted in treatmentemergent keratoacanthomas and squamous cell carcinomas in humans.(8,9) In cynomolgus macaques, subchronic treatment with fresolimumab resulted in reversible epithelial hyperplasia of the bladder, nasal turbinate, and gingiva (with hemorrhage) that”
BackgroundAzaro, A., Rodon, J. A., Carducci, M., Sepúlveda-Sánchez, J. M., Gueorguieva, I., Cleverly, A., Desaiah, D., Namaseevayam, S. P., Holdhoff, M., & Lahn, M. M. F. (2014) · Journal of Medical Cases · doi:10.14740/jmc1966w · Cited by 3
Immunomodulatory, Immunoablative, and Biologic Therapies
van Laar, J. M., & Simms, R. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_41 · Cited by 2
Targeting tumor-associated neutrophils in immunotherapy
Rahmy, S., & Lü, X. (2021) · Elsevier eBooks · doi:10.1016/b978-0-323-85781-9.00006-3 · Cited by 2
Tseng, D., Schultz, L. M., Pardoll, D. M., & Mackall, C. L. (2020) · Elsevier eBooks · doi:10.1016/b978-0-323-47674-4.00006-2 · Cited by 3
Breaking new ground in pulmonary fibrosis: Targeting Pathways and Therapeutic Innovations
Mishra, S. (2025) · The Journal of Association of Chest Physicians · doi:10.4103/jacp.jacp_1_25 · Cited by 1
The interplay between cytokines and immune checkpoints in breast cancer therapy
Wu, Y., Zhu, Y. F., Cang, Q., Shaibu, Z., Kong, L., Zhou, Q., Li, X., & Yin, L. (2026) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2026.189539 · Cited by 2
Amoeboid cancer cells at a glance
Ghose, R., & Sanz‐Moreno, V. (2026) · Journal of Cell Science · doi:10.1242/jcs.264674 · Cited by 2
Liu, L., 陈颖君, Guo, M., Yun, F., Li, X., Chen, L., Li, Y. M., & Li, F. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1782130 · Cited by 1
Ji, L., Hl, L., & Zhu, W. (2026) · Human Cell · doi:10.1007/s13577-026-01430-z · Cited by 1
Strategies for Improving Vaccines to Elicit T Cells to Treat Cancer
Berzofsky, J. A., Wood, L. V., & Terabe, M. (2015) · Cancer drug discovery and develogment/Cancer drug discovery and development · doi:10.1007/978-3-319-21167-1_2 · Cited by 1
Self-citationMizuno, S., & Osaki, E. (2020) · Springer eBooks · doi:10.1007/978-3-030-24432-3_6
Novel Targets in Development for Advanced Renal Cell Carcinoma
Thapa, B., Nelson, A. A., & Kilari, D. (2023) · Springer eBooks · doi:10.1007/978-3-031-40901-1_14 · Cited by 1
Recent Advances in the Use of NK Cells Against Cancer
Gillgrass, A. E., Krneta, T., & Ashkar, A. A. (2014) · Springer eBooks · doi:10.1007/978-3-662-44946-2_18 · Cited by 1
Assessment and Management of Progressive Skin Involvement in Diffuse Scleroderma
Simms, R. W. (2016) · Springer eBooks · doi:10.1007/978-3-319-31407-5_34 · Cited by 1
Sulciner, M. L., Gilligan, M. M., Zetter, B. R., & Panigrahy, D. (2017) · Springer eBooks · doi:10.1007/978-3-319-39147-2_7 · Cited by 1
Recent Advances in the Use of NK Cells Against Cancer
Gillgrass, A. E., Krneta, T., Poznanski, S. M., & Ashkar, A. A. (2020) · Springer eBooks · doi:10.1007/978-3-030-50287-4_17 · Cited by 1
Inflammation and Cancer: Lipid Autacoid and Cytokine Biomarkers of the Tumor Microenvironment
Gilligan, M. M., Zetter, B. R., & Panigrahy, D. (2022) · Springer eBooks · doi:10.1007/978-3-030-98950-7_9 · Cited by 1
TGF-β Signaling Pathway and Its Therapeutic Role in Cancer
James, A. W., Bhat, H. M., Yousuf, S., Jan, M., Rehman, M. U., & Rashid, S. M. (2025) · Springer eBooks · doi:10.1007/978-981-96-2763-9_11 · Cited by 2
Lee, J., Kim, B., & Jung, S. T. (2025) · Seminars in Hematology · doi:10.1053/j.seminhematol.2025.12.003 · Cited by 1
Reigning in regulatory T-cell function
Konopacki, C., Plitas, G., & Rudensky, A. Y. (2015) · Nature Biotechnology · doi:10.1038/nbt.3285 · Cited by 2
Fibrosis: a novel approach for an old problem
(2014) · Receptors & Clinical Investigation · doi:10.14800/rci.151 · Cited by 1
“Single-shot treatment with Fresolimumab against glomeruloschelosis is in phase I ([18]), or in malignant melanoma and renal cell carcinoma ([19]).”
BackgroundRoles of ERK1/2 signaling in LMNA-cardiomyopathy
Chatzifrangkeskou, M. (2016) · theses.fr (ABES) · doi:10.70675/5456db32z6446z4617z9236z7bc0aab104fe
Fibulin-4A in zebrafish development
Khatri, S. (2017) · D-Scholarship@Pitt (University of Pittsburgh)
Immune Checkpoint Combinations with Inflammatory Pathway Modulators
DeVito, N. C., Morse, M. A., Hanks, B. A., & Clarke, J. M. (2017) · Current cancer research · doi:10.1007/978-3-319-63757-0_8
The role of tissue transglutaminase in the progression of colorectal cancer
Ayinde, O. C. (2017) · Aston Publications Explorer (Aston University) · doi:10.48780/publications.aston.ac.uk.00033425
QUANTITATIVE STUDY ON REGULATORY MECHANISMS OF CELL PHENOTYPE TRANSITION
Zhang, J. (2018) · D-Scholarship@Pitt (University of Pittsburgh)
Receptors for Targeting Growth Factors for Treatment of Cancers
Jahagirdar, D., Ghodke, S., Mergu, A., Nikam, A., Devarajan, P. V., Jain, R. D., & Dandekar, P. P. (2019) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-29168-6_7
Biological relationship between bone and myeloma cells
Edwards, C. M., & Lawson, M. A. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00047-5
Anti-cancer Immunologic Function of Recombinant Interleukin-18
Saetang, J. (2018) · PSU Knowledge Bank (Prince of Songkla University)
(Sterling), J. A. R., Johnson, R. W., & Lynch, C. C. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-814841-9.00055-5
Role of epithelial to mesenchymal transition in the resistant mechanism of EGFR-TKIs
Adachi, Y., & Ebi, H. (2023) · Elsevier eBooks · doi:10.1016/b978-0-12-822833-3.00005-x · Cited by 1
Anaz, A. A., Suryaprakash, R. T. C., Shearston, K., & Kujan, O. (2023) · BENTHAM SCIENCE PUBLISHERS eBooks · doi:10.2174/9789815080384123010008
Bintrafusp alfa induced multiple self-healing cutaneous keratoacanthoma-like squamous proliferations
Subhadarshani, S., Waters, M., & Shaughnessy, C. N. (2024) · Clinical and Experimental Dermatology · doi:10.1093/ced/llae034
Additional file 2 of Abnormal signal pathways and tumor heterogeneity in osteosarcoma
Sun, Y., Zhang, C., Fang, Q., Zhang, W., & Liu, W. Y. (2023) · Figshare · doi:10.6084/m9.figshare.22598621
Yuan, J., Jia, J., Wu, T., Zhi, D., Chen, Q., Zhang, J., Wu, Z., Yuan, Z. K., Zhao, X., Liu, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24202645
Additional file 6 of Abnormal signal pathways and tumor heterogeneity in osteosarcoma
Sun, Y., Zhang, C., Fang, Q., Zhang, W., & Liu, W. Y. (2023) · Figshare · doi:10.6084/m9.figshare.22598633
Additional file 5 of Abnormal signal pathways and tumor heterogeneity in osteosarcoma
Sun, Y., Zhang, C., Fang, Q., Zhang, W., & Liu, W. Y. (2023) · Figshare · doi:10.6084/m9.figshare.22598630
Additional file 3 of Abnormal signal pathways and tumor heterogeneity in osteosarcoma
Sun, Y., Zhang, C., Fang, Q., Zhang, W., & Liu, W. Y. (2023) · Figshare · doi:10.6084/m9.figshare.22598624
Additional file 4 of Abnormal signal pathways and tumor heterogeneity in osteosarcoma
Sun, Y., Zhang, C., Fang, Q., Zhang, W., & Liu, W. Y. (2023) · Figshare · doi:10.6084/m9.figshare.22598627
Sachkova, A. A., Rysina, Y. D., Svirshchevskaya, E. V., Grishin, I. D., Fedorov, A. Y., & Shchegravina, E. S. (2024) · Russian Journal of Organic Chemistry · doi:10.1134/s107042802404016x
Plichta, J., Majos, A., Kuna, P., & Panek, M. (2024) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2024.12735 · Cited by 1
“Fresolimumab (or GC1008) is an example of such a therapeutic, an anti‑TGF‑ β antibody developed by Genzyme which was shown to exhibit antitumor activity in renal carcinomas and melanomas with an accept‑ able safety profile (88).”
BackgroundTGF-β in tumor microenvironment, metabolism, and immunotherapy
Bai, H., & Wan, Y. Y. (2024) · Elsevier eBooks · doi:10.1016/b978-0-443-13827-0.00017-2
Characterization of the mechanisms of action of the transcription factor ZEB1 in melanoma
Tang, Y. (2021) · theses.fr (ABES) · doi:10.70675/d147bc89z14e4z4137zadecz307fd2f27136
Plichta, J., Karbownik, M. S., Kuna, P., & Panek, M. (2025) · Journal of Cellular and Molecular Medicine · doi:10.1111/jcmm.70548
Biological Factors in Maintaining Joint Health
Knezic, N., Singer, J., Lind, D. R. G., Groesbeck, A., Luhmann, M., Lopez, L., Robinson, S., & Huard, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-84693-9_7
Updates and Review of Neoadjuvant Therapy for Resectable Pancreatic Cancer
Cobb, W., Rozefort, D., Ji, C., Sehgal, S., Rosales, A., & Sehgal, R. (2025) · Oncology · doi:10.1159/000548583 · Cited by 2
“Fresolimumab is a monoclonal antibody targeting TGF-β and is currently being investigated in several clinical trials for cancer therapy [52].”
Yuan, J., Jia, J., Wu, T., Du, Z., Chen, Q., Zhang, J., Wu, Z., Yuan, Z. K., Zhao, X., Liu, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24202654
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26704773
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26704767
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26704761
Huang, Q., Liu, M., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., & Dong, J.-T. (2023) · Figshare · doi:10.6084/m9.figshare.22607072
Huang, Q., Liu, M., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., & Dong, J.-T. (2023) · Figshare · doi:10.6084/m9.figshare.22607069
Li, Y., Li, J., Zhou, L., Wang, Z., Jin, L., Cao, J., Xie, H., & Wang, L. (2024) · Figshare · doi:10.6084/m9.figshare.25763082
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25584037
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26704758
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.25583896
Huang, Q., Liu, M., Zhang, D., Lin, B.-B., Fu, X., Zhang, Z., Zhang, B., & Dong, J.-T. (2023) · Figshare · doi:10.6084/m9.figshare.22607066
Yuan, J., Jia, J., Wu, T., Du, Z., Chen, Q., Zhang, J., Wu, Z., Yuan, Z. K., Zhao, X., Liu, J., et al. (2023) · Figshare · doi:10.6084/m9.figshare.24202660
Understanding the role of extrinsic regulators in normal and malignant haematopoiesis
Belmonte, M. (2021) · Apollo (University of Cambridge) · doi:10.17863/cam.72569
Li, Y., Li, J., Zhou, L. F., Wang, Z., Jin, L., Cao, J., Xie, H., & Wang, L. (2024) · Figshare · doi:10.6084/m9.figshare.25762885
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26704770
Guo, Y., Wang, Z., Zhou, H., Pan, H., Han, W., Deng, Y., Li, Q., Xue, J., Ge, X., Wang, S., et al. (2024) · Figshare · doi:10.6084/m9.figshare.26704764
Additional file 1 of Abnormal signal pathways and tumor heterogeneity in osteosarcoma
Sun, Y., Zhang, C., Fang, Q., Zhang, W., & Liu, W. (2023) · Figshare · doi:10.6084/m9.figshare.22598618
Lanauze, C. B. (2001) · Scholarly Commons (University of Pennsylvania)
Biomolecular approaches to endocrine-related cancers: from diagnostics to targeted therapies
BORGES DE SOUZA, P. (2023) · Institutional Research Information System University of Ferrara (University of Ferrara)
Onderzoek naar de rol van GARP door gebruik van cel-specifieke knock-out muizen
Vermeersch, E. (2018) · Lirias
Devi-Marulkar, P. (2015) · theses.fr (ABES) · doi:10.70675/1afef94czc6daz4936zb0d3z44f75d1762b1
Guilcher, C. L. (2018) · theses.fr (ABES) · doi:10.70675/31755573zc52bz4020zb736za39dcd3e9230
Identification et modulation des voies moléculaires impliquées dans l’agressivité du mélanome cutané
Gautron, A. (2019) · theses.fr (ABES) · doi:10.70675/b9c75939z7407z49abzafcbze6e92703d459
The Elovl5 enzyme in breast cancer : regulation of cancer cell proliferation and metastasis
Kieu, T. (2021) · theses.fr (ABES) · doi:10.70675/09ffad1dzef26z436ez94eezf8f77c83e342
Lecacheur, M. (2021) · theses.fr (ABES) · doi:10.70675/9c0b4d17zd8d8z498ezb534z3096acf22d56
Li, J., Liu, T., Xiao, W., Zhao, D., Li, Q., Liu, S., Li, X., Tong, Y., Li, H., Jiang, H., et al. (2026) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2025-014473
“16 However, treatment with TGF-β blockade using either a neutralizing antibody or a small-molecule inhibitor in patients with advanced melanoma yielded a limited objective response rate, 17 possibly due to the pleiotropic nature of TGF-β signaling across different cell types.”
Progress in Designing Cytokine Antagonist Antibodies for Cancer Therapy
McEacheron, H., Nisita, G., Liu, P., & Spangler, J. B. (2026) · BioDrugs · doi:10.1007/s40259-026-00777-x
“Fresolimumab, an antagonistic anti-human TGF-β human IgG4κ antibody (GC1008, Sanofi Inc.) that neutralizes all isoforms of TGF-β, was assessed in a phase I study of advanced malignant melanoma or renal cell carcinoma and showed preliminary evidence of antitumor activity (NCT00356460) [216].”
Tai, S.-B., Yang, J., Liu, P., & Chen, C.-L. (2026) · EXCLI journal · doi:10.17179/excli2026-9381 · Cited by 1
Collagen-derived biomarkers reveal distinct fibrotic responses among cancer-associated fibroblasts
Hettich, A., Karsdal, M. A., & Willumsen, N. (2026) · Scientific Reports · doi:10.1038/s41598-026-57423-3
“Additionally, cells were treated with Fresolimumab (GC1008), a human monoclonal antibody that neutralizes all TGF-β isoforms and has shown therapeutic potential in various cancers, including melanoma, renal carcinoma, and metastatic breast cancer 50 .”
Palazzo, G., Tinnirello, V., Bivona, G., Ghersi, G., & Campora, S. (2026) · Biology · doi:10.3390/biology15141167
Spatial ecotype in tumor immune exclusion: from spatial architecture to therapeutic strategies
Ying, M., Zhang, L., Jia, M., Sun, X., Su, Y., Liu, C., Gong, M., Sun, T., & Zhang, B. (2026) · Molecular Cancer · doi:10.1186/s12943-026-02766-8 · Cited by 1
Metadata
- Authors
- Morris, J. C., Tan, A. R., Olencki, T. E., Shapiro, G. I., Dezube, B. J., Reiss, M., Hsu, F. J., Berzofsky, J. A., & Lawrence, D. P.
- Affiliations
- National Cancer Institute (US)
- Rutgers Cancer Institute (US)
- The Ohio State University (US)
- Dana-Farber Cancer Institute (US)
- Beth Israel Deaconess Medical Center (US)
- Massachusetts General Hospital (US)
- Corresponding author
- Morris, John C.
- Berzofsky, Jay A.
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2014-03-11
- Volume
- 9
- Issue
- 3
- Pages
- e90353
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC3949712
- OpenAlex
- W2075873658
- Cited by
- 487
- References
- 50
- Citations by year
- 2026: 29 · 2025: 39 · 2024: 48 · 2023: 47 · 2022: 36 · 2021: 46 · 2020: 49 · 2019: 30 · 2018: 29 · 2017: 41 · 2016: 30 · 2015: 29 · 2014: 9
- FWCI
- 14.89
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- PLoS ONE (publishedVersion, public-domain)
- Europe PMC (PubMed Central) (publishedVersion, other-oa)
- PubMed Central (publishedVersion, public-domain)
- PubMed (publishedVersion)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- Figshare (submittedVersion, cc-by)
- Funders
- Massachusetts General Hospital
- Ohio State University
- Rutgers Cancer Institute of New Jersey
- National Institutes of Health
- National Cancer Institute
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › TGF-β signaling in diseases
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- TGF-beta, melanoma, renal cell carcinoma, advanced cancer, dose escalation, safety, pharmacokinetics, keratoacanthoma, squamous cell carcinoma, anticancer activity, progression-free survival
- MeSH terms
- Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Antineoplastic Agents, Carcinoma, Renal Cell, Female, Humans, Kidney Neoplasms, Male, Melanoma, Middle Aged, Neoplasm Staging, Tomography, X-Ray Computed, Transforming Growth Factor beta, Treatment Outcome, Positron-Emission Tomography, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.